Classifications

• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
  • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
  • C08G63/66—Polyesters containing oxygen in the form of ether groups
  • C08G63/664—Polyesters containing oxygen in the form of ether groups derived from hydroxy carboxylic acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
  • A61K9/1605—Excipients; Inactive ingredients
  • A61K9/1629—Organic macromolecular compounds
  • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
  • A61K9/1605—Excipients; Inactive ingredients
  • A61K9/1629—Organic macromolecular compounds
  • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
  • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
  • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
  • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
  • C08B37/0084—Guluromannuronans, e.g. alginic acid, i.e. D-mannuronic acid and D-guluronic acid units linked with alternating alpha- and beta-1,4-glycosidic bonds; Derivatives thereof, e.g. alginates
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
  • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
  • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
  • C08G69/26—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from polyamines and polycarboxylic acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
  • A61K9/1605—Excipients; Inactive ingredients
  • A61K9/1629—Organic macromolecular compounds
  • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
  • A61K9/1605—Excipients; Inactive ingredients
  • A61K9/1629—Organic macromolecular compounds
  • A61K9/1658—Proteins, e.g. albumin, gelatin

Definitions

• the invention relates to biodegradable polymer composites for the production of microcapsules of any ingredients, such as e.g. Food, pharmaceuticals and immunogens or materials of the art such as e.g. Oils, dyes, enzymes etc.
• the matrix, shell / capsule materials used mono-, di- and polysaccharides, proteins, polyamino acids, polycarboxylic acids, poly (lactide-co-glycolide), acrylates, polyalcohols and their copolymers, liposomes, silicate, etc. in various combinations and mixing ratios ) and
• Transport vehicle functions in the intended area of activity and only at the destination
• US Pat. No. 5,700,486 discloses biodegradable polymers or copolymers in pharmaceutical compositions for the formation of particles which are used for the controlled release of pharmacologically active substances.
• the compositions listed consistently represent physical mixtures of the uniform polymers and copolymers, the proportions of which are varied before the encapsulation process.
• the disadvantage of such biodegradable polymers is that the substance release is neither targeted nor by defined enzyme action.
• US-A 5,686,113 describes the microencapsulation in aqueous solutions.
• the biodegradable capsule material used is a mixture of an anionic polymer or its salts and an amino-functionalized monomer, the formation of the Reaction product takes place during the microencapsulation.
• Such mixtures have the disadvantage that the formation reaction of microcapsules cannot take place simultaneously in aqueous and also in non-aqueous systems.
• the particles can bind selectively to certain ligands, but a specific dissolution of the capsule wall at the binding site is not possible.
• the object of the invention is to find biodegradable components which allow a technically simple process for the production of microcapsules of any ingredients and both for the temporary separation of any materials, such as e.g. Oils, dyes, enzymes, drugs, immunogens, nucleic acids, etc. from the surrounding environment, as well as or for a targeted transport and controllable release of active pharmaceutical ingredients.
• any materials such as e.g. Oils, dyes, enzymes, drugs, immunogens, nucleic acids, etc.
• a polymer composite is suitable as the capsule wall material, which is a uniform reaction product and has covalent bonds between the substructures, at least one of the components used having hydrophilic properties.
• This composite allows the formation of microcapsules from solid or dissolved substances or preparations in both aqueous and non-aqueous systems.
• biodegradable polymers according to the invention only bind to defined ligands and are only broken down into subunits under the influence of known factors.
• the new polymers can be used for different applications.
• Capsule materials are produced which bind to target cells according to their intended use, can be absorbed by them or dissolve on the cell surface or inside the cell.
• This basic concept of the chemical connection of non-degradable or poorly degradable substances with substances that are specifically split by certain enzymes (composites) is used for a wide variety of biological and technical fields of application
• polyester polyamides or polysaccharides
• R 1 and R 2 denote the same or different end groups or protective groups or receptor molecules or markers, i, n and m are from the range of natural numbers and can assume zero or one in individual cases,
• Q is an at least bifunctional structure with hydrophilic properties, derived from the
• Fields of polyols, polyamides and polyesters, means used as capsule wall material, which is used to split the bonds between the
• Substructures R, P and / or as well as within Q an enzymatic recognition and / or
• Polymers with structural elements of hydroxycarboxylic acids, their salts or esters are particularly preferred for P 1 and P ". They are preferably polyesters, such as polyglycolides, polylactides, poly (hydroxybutyric acids) or copolymers resulting therefrom, polysaccharides, such as polygalacturonic acid or alginic acid.
• R 1 and / or R 2 are acyl, alkyl or alkoxycarbonyl groups
• R 1 and / or R 2 are markers, receptors or other molecules which bind specifically to structures, preferably from the substance classes of the oligopeptides, proteins, glycoproteins and oligonucleotides
• Receptor molecules are preferably lectins, receptor ligands or antibodies.
• Compounds which are derived from mono-, oligo- or polysaccharides and which optionally have amino or carboxy groups or for compounds which are derived from di-, oligo- or polypeptides are particularly suitable as structural element Q.
• the structural element Q preferably has enzyme recognition and cut parts, preferably it has a di- or polysaccharide. or an oligopeptide with a defined protease interface.
• the composite material according to the invention is used to produce microcapsules of substances, for example pollutants, such as mineral oil, for temporary separation from the surrounding environment.
• the use of the composites according to the invention with different marker or receptor molecules R 1 and / or R 2 has the advantage that they recognize extracellular and / or intracellular structures.
• a targeted transport and a targeted release of active substances can take place at the site of action of immunologically and or pharmacologically / toxicically active substances.
• microcapsules with any ingredients e.g. Solid or dissolved materials from the fields of food, pharmaceutical preparations or technical products or additives using the composites according to the invention are carried out according to processes known per se in organic solvents or aqueous emulsions, e.g. through core-shell processes.
• Lectin Lectin UEA I (Ulex Europaeus)
• MS-PLA 2000 O-maleoyl polylactide 2000
• Example 2 Composite of O-acetyl polylactide 2000 and dihistidine
• Example 3 Composite of O-chloroacetyl polylactide 17000 and a cysteine-rich peptide
• Example 7 Composite of O-acetyl polylactide 2000 and lactose
• Example 8 Composite of O-acetyl polylactide 17000 and lactose
• Example 9 Composite of O-acetyl polylactide 2000 and dextran 6000
• Example 10 Composite of O-Maleoyl-polylactide 2000 and the lectin UEA I
• MS-PLA2000 (0.736 mg) and EDC (0.269 mg) are suspended in 0.1 M MES buffer solution (1 ml) and activated for 30 min at room temperature in an ultrasonic bath.
• the lectin UEA I (10 mg) is added and the mixture is shaken at room temperature for 2 h. The solid is then centrifuged (3000 rpm, 10 min), washed twice with water and freeze-dried.
• Example 11 Composite of O-Maleoyl-Polylactid 2000 and Albumin (BSA) MS-PLA2000 (0.736 mg) and EDC (0.269 mg) are suspended in 0.1 M MES buffer solution (1 ml) and activated for 30 min at room temperature in an ultrasonic bath. BSA (20 mg) is added and the mixture is shaken at room temperature for 2 hours. The solid is then centrifuged (3000 rpm, 10 min), washed twice with water and freeze-dried.
• BSA O-Maleoyl-Polylactid 2000 and Albumin
• Example 12 Microencapsulation of a Rabbit IgG preparation with a composite according to Example 8.
• 1 g of a lyophilized Rabbit IgG preparation (grain size 1 to 5 ⁇ m) is suspended in 100 ml of petroleum ether (80 - 110 ° C) by stirring. A solution of 1 g of composite from Example 8 and 5 ml of acetone in 10 portions is added dropwise within 5 h. Allow to stir for another hour. After sedimentation, the suspension is filtered, washed with 20 ml of petroleum ether and air-dried.
• polylactide 17000 and the corresponding composite material according to Example 8 were used as
• the release studies are carried out in an incubation shaker at 37 ° C in PBS buffer at pH 7.3. 200 mg of particles are suspended in 10 ml of PBS buffer.
• Example 13 Microencapsulation of albumin (BSA) with a composite according to Example 7
• Example 14 Microencapsulation of albumin (BSA) with a composite according to Example 7 by means of spray drying
• BSA 400 mg BSA are dissolved in 200 ml water.
• a solution of 20 g composite according to Example 7 is dispersed in 100 ml methylene chloride in such a way that the methylene chloride almost completely evaporated and a stable emulsion is formed. This emulsion is then spray dried.
• Example 15 Core-Shell Encapsulation of Rabbit IgG / PLA 17000 Cores with Composites According to Example 10
• a solution of 0.05 g of composite according to Example 10 and 0.05 g of PLA 17000 in 2 ml of acetone is added dropwise. Allow to stir for another hour. After sedimentation, the suspension is filtered, washed with 20 ml of petroleum ether and air-dried.
• Example 16 Microencapsulation of silicate particles (impregnated with amaranth) with a composite according to Example 7
• the release studies are carried out in an incubation shaker at 37 ° C in PBS buffer at pH 7.3. 200 mg of particles are suspended in 10 ml of PBS buffer. To study the influence of the enzyme on the stability of the particle shell, ß-galactosidase (20 units) is added before the particle is added. 500 ⁇ l of solution are removed at intervals of 30 minutes and analyzed for the content of amaranth by spectrophotometry at a wavelength of 520 nm. The results are summarized in Fig. 3.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• Polymers & Plastics (AREA)
• General Health & Medical Sciences (AREA)
• Epidemiology (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Materials Engineering (AREA)
• Biochemistry (AREA)
• Molecular Biology (AREA)
• Medicinal Preparation (AREA)
• Manufacturing Of Micro-Capsules (AREA)
• Peptides Or Proteins (AREA)
• Polyamides (AREA)
• Polyesters Or Polycarbonates (AREA)
• General Preparation And Processing Of Foods (AREA)
• Formation And Processing Of Food Products (AREA)
• Polysaccharides And Polysaccharide Derivatives (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=7898210

Family Applications (1)

Country Status (9)

Families Citing this family (18)

Family Cites Families (6)

• 2000
  • 2000-02-20 CN CN00803893A patent/CN1339964A/zh active Pending
  • 2000-02-20 CA CA002362263A patent/CA2362263A1/en not_active Abandoned
  • 2000-02-20 DE DE10008880A patent/DE10008880A1/de not_active Withdrawn
  • 2000-02-20 EP EP00925026A patent/EP1154760A1/de not_active Withdrawn
  • 2000-02-20 AU AU43902/00A patent/AU4390200A/en not_active Abandoned
  • 2000-02-20 WO PCT/DE2000/000526 patent/WO2000048573A1/de not_active Application Discontinuation
  • 2000-02-20 RU RU2001125666/04A patent/RU2001125666A/ru unknown
  • 2000-02-20 JP JP2000599365A patent/JP2002537415A/ja active Pending
• 2001
  • 2001-08-17 US US09/932,761 patent/US20020147296A1/en not_active Abandoned

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events